Compare Novartis AG (NVS) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $30.85, down 0.13% for the day, with a bearish technical signal driven by moving averages. The stock faces significant long-term erosion, as highlighted by a recent article showing a $10,000 investment five years ago would now be worth about $1,527. Key support lies at $30, with resistance at $31.

The outlook remains challenged by interest rate sensitivity and leverage decay, posing risks for investors seeking Treasury exposure. Opportunities may arise from potential Federal Reserve policy shifts, but volatility and structural ETF risks demand caution.